Neurogenic Detrusor Overactivity (NDO) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Neurogenic Detrusor Overactivity Emerging Therapy and TPP Insights

Thelansis’s “Neurogenic Detrusor Overactivity (NDO) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Neurogenic Detrusor Overactivity Overview

Neurogenic detrusor overactivity (NDO) is a manifestation of neurogenic lower urinary tract dysfunction characterized by involuntary detrusor contractions during bladder filling, often causing urgency, urinary incontinence, and abnormal storage pressures. In patients with poor bladder compliance or high detrusor pressure, inadequate management can threaten the upper urinary tract and contribute to recurrent infections and renal morbidity. Current treatment aims primarily to protect the upper urinary tract while improving continence and quality of life, using intermittent catheterization when emptying is impaired and pharmacologic therapy with antimuscarinics or beta-3 agonists. When medication is inadequate, intradetrusor botulinum toxin A provides an established, effective option, although repeated procedures and the risk of increased residual urine or urinary retention can create substantial treatment burden. This has encouraged investigation of more convenient, localized approaches, including sustained intravesical drug delivery and neuromodulation, although the development maturity of these strategies varies and several remain investigational. An earlier clinical study of the trospium-releasing TAR-302-5018 intravesical system demonstrated the feasibility of prolonged local delivery but was completed several years ago. For stakeholders, NDO represents a high-value functional-urology opportunity where reducing procedural burden while maintaining low-pressure bladder function and protecting the upper urinary tract remains a central unmet need.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)